When does Cimzia’s patent protection expire?
Cimzia (certolizumab pegol) is a biologic, and its “patent expiry” depends on which specific patent, country, and exclusivity type you mean (for example, patents on the active molecule vs. patents on formulations, manufacturing, or specific indications). With only the question provided, there isn’t enough information to state a single exact expiry date.
Which countries’ patent expiry dates matter most?
In practice, patients and companies usually care about:
- U.S. patent and exclusivity timelines
- European Union (EU) patent and regulatory exclusivity timelines
- U.K. timelines after Brexit
- Japan and other major markets
Each jurisdiction can have different legal instruments (patents, supplementary protection certificates where applicable, and regulatory data exclusivity).
Does “patent expiry” mean the same thing as “biosimilar launch”?
Not exactly. Even after one set of patents expires, other patents (or regulatory exclusivities) can still block biosimilar entry. Biosimilars can launch only after the combination of:
- patent landscape constraints, and
- any applicable regulatory exclusivity periods
is satisfied.
So the “last barrier to entry” can be later than the first patent expiration date.
What should you look up to get the exact expiry date for Cimzia?
To identify the correct expiry date, you typically need:
- The jurisdiction (e.g., U.S. vs EU/UK)
- The exact Cimzia product labeling being protected in that region
- The patent family (active ingredient vs process vs formulation vs indication)
- Whether an exclusivity term (not a patent) applies
If you tell me these details, I can narrow it to a specific date
Reply with:
1) Country/region (U.S., EU, U.K., etc.)
2) Whether you mean the original certolizumab pegol product or a specific formulation/indication
3) Whether you’re looking for “last patent expiry” or “earliest biosimilar launch”
Sources: None provided in the prompt.